{"id":535339,"date":"2021-09-08T07:03:02","date_gmt":"2021-09-08T11:03:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\/"},"modified":"2021-09-08T07:03:02","modified_gmt":"2021-09-08T11:03:02","slug":"finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\/","title":{"rendered":"Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOMERVILLE, Mass., Sept.  08, 2021  (GLOBE NEWSWIRE) &#8212; Finch Therapeutics Group, Inc. (\u201cFinch\u201d or \u201cFinch Therapeutics\u201d) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its <em>Human-First Discovery<sup>\u00ae<\/sup><\/em> platform to develop a novel class of orally administered biological drugs, today announced the appointment of Marc Blaustein as Chief Operating Officer. Mr. Blaustein is a seasoned biopharmaceutical executive with more than 20 years of experience building and leading companies and critical business functions including operations, business development, program management, and manufacturing.<\/p>\n<p>\u201cI am delighted to welcome Marc to the Finch team at a time when we are positioned to make significant advancements across our microbiome therapeutics platform,\u201d said Mark Smith, PhD, Chief Executive Officer of Finch Therapeutics. \u201cMarc has demonstrated immediate impact within the companies he joins and we believe his broad skillset and successful track record in drug development and commercialization will be invaluable to our organization. I look forward to leveraging Marc\u2019s experience and operational expertise as Finch enters its next phase of growth, with our lead candidate in late-stage clinical development and a growing pipeline of programs headed towards the clinic with an expected data-rich period ahead.\u201d<\/p>\n<p>\u201cThe field of microbiome therapeutics is an incredibly exciting emerging target for innovation and Finch\u2019s platform offers a novel modality to potentially address a wide range of serious unmet medical needs. I am thrilled to join Finch at such a pivotal time and hope to draw from my experience to continue building upon the momentum generated by Finch\u2019s promising clinical data and translational research,\u201d said Mr. Blaustein.<\/p>\n<p>Mr. Blaustein most recently consulted as the Head of Business Development for Guide Therapeutics, which was acquired by Beam Therapeutics in 2021. Prior to Guide Therapeutics, Mr. Blaustein was the Chief Executive Officer of NED Biosystems and co-founder and Chief Executive Officer of Akashi Therapeutics. Before founding Akashi, he served in various leadership positions across several biotechnology companies, including Senior Vice President of Manufacturing, Process and Commercial Operations at Dyax Corp. (now Takeda), where he led the development of Kalbitor<sup>\u00ae<\/sup>. Prior to Dyax, Mr. Blaustein held business development and management roles at Alkermes, where he initiated and led the development program for Vivitrol<sup>\u00ae<\/sup>. Prior to Alkermes, Mr. Blaustein worked in business development at Genetics Institute (now Pfizer). Mr. Blaustein began his career in management consulting, first at Mercer Management Consulting, and then as a founding partner of Northbridge Consulting. Mr. Blaustein received his master\u2019s degree in Public Policy from Harvard University and bachelor\u2019s degree in Biology from the University of Pennsylvania. He is also a Chartered Financial Analyst (CFA) charterholder.<\/p>\n<p>\n        <strong>About Finch Therapeutics<\/strong>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TAVD__vfFRITyLQKpF3H4_Zd88g7wtNQ1iOBFw0mKnwkfbRAF_WyhwzTKcDzS9SDed1Z_9PffeMbNZ96TeGV1j_W2T4q0uoXThAM5vlb6_0=\" rel=\"nofollow noopener\" target=\"_blank\">Finch Therapeutics<\/a> is a clinical-stage microbiome therapeutics company leveraging its <em>Human-First Discovery<\/em><sup>\u00ae<\/sup> platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch\u2019s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent <em>C. difficile<\/em> infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. PRISM4, a Phase 3 trial, is designed to serve as the second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. Finch has a partnership with Takeda focused on the development of targeted microbiome therapeutics for inflammatory bowel disease.<\/p>\n<p>\n        <em>Human-First Discovery<\/em><br \/>\n        <sup>\u00ae<\/sup>\u00a0is a registered trademark of Finch Therapeutics Group, Inc.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Statements contained in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; \u201cplans,\u201d \u201cpotential,\u201d &#8220;projects,\u201d \u201cwould\u201d and &#8220;future&#8221; or similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding: Finch\u2019s strategy and plans, including in regards to development activities as well as Finch\u2019s ability to advance a novel class of therapeutics across its platform and pipeline. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Finch\u2019s limited operating history and historical losses; Finch\u2019s ability to raise additional funding to complete the development and any commercialization of its product candidates; Finch\u2019s dependence on the success of its lead product candidate, CP101; the possibility that Finch may be delayed in initiating, enrolling or completing any clinical trials; results of clinical trials may not be indicative of final or future results from later stage or larger clinical trials (or in broader patient populations once the product is approved for use by regulatory agencies) or may not be favorable or may not support further development; Finch\u2019s product candidates may not generate the benefits to patients that are anticipated; anticipated regulatory approvals may be delayed or refused; competition from third parties that are developing products for similar uses; Finch\u2019s ability to maintain patent and other intellectual property protection and the possibility that Finch\u2019s intellectual property rights may be infringed, invalid or unenforceable or will be threatened by third parties; Finch\u2019s ability to qualify and scale its manufacturing capabilities in anticipation of commencement of multiple global clinical trials; Finch\u2019s lack of experience in selling, marketing and distributing its product candidates; Finch\u2019s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies; and risks relating to the impact and duration of the COVID-19 pandemic on Finch\u2019s business. These and other risks are described more fully in Finch\u2019s filings with the Securities and Exchange Commission (\u201cSEC\u201d), including the section titled \u201cRisk Factors\u201d in in Finch\u2019s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2021, as well as discussions of potential risks, uncertainties, and other important factors in Finch\u2019s other filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Finch undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong>\n      <\/p>\n<p>Laurence Watts<br \/>Gilmartin Group<br \/>(619) 916-7620<br \/>laurence@gilmartinir.com<\/p>\n<p>or<\/p>\n<p>Stephen Jasper<br \/>Gilmartin Group<br \/>(858) 525-2047<br \/>stephen@gilmartinir.com<\/p>\n<p>\n        <strong>Media Contact:<\/strong>\n      <\/p>\n<p>Jenna Urban<br \/>Berry &amp; Company Public Relations<br \/>(212) 253-8881<br \/>jurban@berrypr.com<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTYzOCM0MzkzMDYzIzIxOTI4ODQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YTM2ZThiMTMtZDBlMi00ZDk3LTk4MjUtZTViN2U3N2VmNTM0LTEyMDQ0Mzc=\/tiny\/Finch-Therapeutics-Group-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOMERVILLE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Finch Therapeutics Group, Inc. (\u201cFinch\u201d or \u201cFinch Therapeutics\u201d) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery\u00ae platform to develop a novel class of orally administered biological drugs, today announced the appointment of Marc Blaustein as Chief Operating Officer. Mr. Blaustein is a seasoned biopharmaceutical executive with more than 20 years of experience building and leading companies and critical business functions including operations, business development, program management, and manufacturing. \u201cI am delighted to welcome Marc to the Finch team at a time when we are positioned to make significant advancements across our microbiome therapeutics platform,\u201d said Mark Smith, PhD, Chief Executive Officer of Finch Therapeutics. \u201cMarc has demonstrated immediate impact &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-535339","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOMERVILLE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Finch Therapeutics Group, Inc. (\u201cFinch\u201d or \u201cFinch Therapeutics\u201d) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery\u00ae platform to develop a novel class of orally administered biological drugs, today announced the appointment of Marc Blaustein as Chief Operating Officer. Mr. Blaustein is a seasoned biopharmaceutical executive with more than 20 years of experience building and leading companies and critical business functions including operations, business development, program management, and manufacturing. \u201cI am delighted to welcome Marc to the Finch team at a time when we are positioned to make significant advancements across our microbiome therapeutics platform,\u201d said Mark Smith, PhD, Chief Executive Officer of Finch Therapeutics. \u201cMarc has demonstrated immediate impact &hellip; Continue reading &quot;Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-08T11:03:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTYzOCM0MzkzMDYzIzIxOTI4ODQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer\",\"datePublished\":\"2021-09-08T11:03:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\\\/\"},\"wordCount\":1126,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTYzOCM0MzkzMDYzIzIxOTI4ODQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\\\/\",\"name\":\"Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTYzOCM0MzkzMDYzIzIxOTI4ODQ=\",\"datePublished\":\"2021-09-08T11:03:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTYzOCM0MzkzMDYzIzIxOTI4ODQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTYzOCM0MzkzMDYzIzIxOTI4ODQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\/","og_locale":"en_US","og_type":"article","og_title":"Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer - Market Newsdesk","og_description":"SOMERVILLE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Finch Therapeutics Group, Inc. (\u201cFinch\u201d or \u201cFinch Therapeutics\u201d) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery\u00ae platform to develop a novel class of orally administered biological drugs, today announced the appointment of Marc Blaustein as Chief Operating Officer. Mr. Blaustein is a seasoned biopharmaceutical executive with more than 20 years of experience building and leading companies and critical business functions including operations, business development, program management, and manufacturing. \u201cI am delighted to welcome Marc to the Finch team at a time when we are positioned to make significant advancements across our microbiome therapeutics platform,\u201d said Mark Smith, PhD, Chief Executive Officer of Finch Therapeutics. \u201cMarc has demonstrated immediate impact &hellip; Continue reading \"Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-08T11:03:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTYzOCM0MzkzMDYzIzIxOTI4ODQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer","datePublished":"2021-09-08T11:03:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\/"},"wordCount":1126,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTYzOCM0MzkzMDYzIzIxOTI4ODQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\/","name":"Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTYzOCM0MzkzMDYzIzIxOTI4ODQ=","datePublished":"2021-09-08T11:03:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTYzOCM0MzkzMDYzIzIxOTI4ODQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTYzOCM0MzkzMDYzIzIxOTI4ODQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-announces-the-appointment-of-marc-blaustein-as-chief-operating-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=535339"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535339\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=535339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=535339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=535339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}